Literature DB >> 33301825

The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis.

Vicente Arroyo1, Paolo Angeli2, Richard Moreau3, Rajiv Jalan4, Joan Clària5, Jonel Trebicka6, Javier Fernández5, Thierry Gustot7, Paolo Caraceni8, Mauro Bernardi8.   

Abstract

Acute decompensation (AD) of cirrhosis is defined by the development of ascites, hepatic encephalopathy and/or variceal bleeding. Ascites is traditionally attributed to splanchnic arterial vasodilation and left ventricular dysfunction, hepatic encephalopathy to hyperammonaemia, and variceal haemorrhage to portal hypertension. Recent large-scale European observational studies have shown that systemic inflammation is a hallmark of AD. Here we present a working hypothesis, the systemic inflammation hypothesis, suggesting that systemic inflammation through an impairment of the functions of one or more of the major organ systems may be a common theme and act synergistically with the traditional mechanisms involved in the development of AD. Systemic inflammation may impair organ system function through mechanisms which are not mutually exclusive. The first mechanism is a nitric oxide-mediated accentuation of the preexisting splanchnic vasodilation, resulting in the overactivation of the endogenous vasoconstrictor systems which elicit intense vasoconstriction and hypoperfusion in certain vascular beds, in particular the renal circulation. Second, systemic inflammation may cause immune-mediated tissue damage, a process called immunopathology. Finally, systemic inflammation may induce important metabolic changes. Indeed, systemic inflammatory responses are energetically expensive processes, requiring reallocation of nutrients (glucose, amino acids and lipids) to fuel immune activation. Systemic inflammation also inhibits nutrient consumption in peripheral (non-immune) organs, an effect that may provide one mechanism of reallocation and prioritisation of metabolic fuels for inflammatory responses. However, the decrease in nutrient consumption in peripheral organs may result in decreased mitochondrial production of ATP (energy) and subsequently impaired organ function.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACLF; Acute-on-chronic liver failure; Bacterial infections; Metabolism; Pre-ACLF; Stable decompensated cirrhosis; Systemic inflammation; Unstable decompensated cirrhosis

Mesh:

Year:  2020        PMID: 33301825     DOI: 10.1016/j.jhep.2020.11.048

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

1.  Identifying the four shades of acute decompensation of cirrhosis.

Authors:  Carmine Gambino; Salvatore Piano
Journal:  United European Gastroenterol J       Date:  2021-05-03       Impact factor: 4.623

2.  Predicting development of ACLF.

Authors:  Jordan Hindson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09       Impact factor: 46.802

Review 3.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

Review 4.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

5.  Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.

Authors:  Theresa Bucsics; Katharina Lampichler; Constantin Vierziger; Maria Schoder; Florian Wolf; David Bauer; Benedikt Simbrunner; Lukas Hartl; Mathias Jachs; Bernhard Scheiner; Michael Trauner; Thomas Gruenberger; Franz Karnel; Mattias Mandorfer; Thomas Reiberger
Journal:  Dig Dis Sci       Date:  2022-03-17       Impact factor: 3.199

Review 6.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

7.  Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC).

Authors:  Sanchit Sharma; Samagra Agarwal; Anoop Saraya; Shiv Kumar Sarin; Ashok Choudhury; Mamun Al Mahtab; Mohd Shahinul Alam; Sanjiv Saigal; Dong Joon Kim; C E Eapen; Ashish Goel; Qin Ning; Harshad Devarbhavi; Virendra Singh; Akash Shukla; Saeed Hamid; Jinhua Hu; Soek-Siam Tan; Anil Arora; Manoj Kumar Sahu; Mohd Rela; Dinesh Jothimani; P N Rao; Anand Kulkarni; Hashmik Ghaznian; Guan Huei Lee; Duan Zhongping; Ajit Sood; Omesh Goyal; Laurentius A Lesmana; Rinaldi C Lesmana; Sombat Treeprasertsuk; Nan Yuemin; Samir Shah; Han Tao; V M Dayal; Xin Shaojie; Fazal Karim; Zaigham Abbas; Jose D Sollano; Kemal Fariz Kalista; Ananta Shreshtha; Diana Payawal; Masao Omata
Journal:  Hepatol Int       Date:  2022-07-18       Impact factor: 9.029

Review 8.  Sarcopenia and frailty in decompensated cirrhosis.

Authors:  Puneeta Tandon; Aldo J Montano-Loza; Jennifer C Lai; Srinivasan Dasarathy; Manuela Merli
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 9.  The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2021-06-18       Impact factor: 4.162

Review 10.  Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.

Authors:  Cornelius Engelmann; Joan Clària; Gyongyi Szabo; Jaume Bosch; Mauro Bernardi
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.